… In conclusion, our study supports the use of molnupiravir in non-hospitalized patients with
COVID-19. Further research should be focused on evaluating its comparative efficacy in …

… trial of therapeutics for COVID-19 in nonhospitalized adults. … study in adults with mild-to-moderate
COVID-19 randomized … Primary outcomes were time to improvement in COVID-19 …

… are not hospitalized, and PASC among these non-hospitalized individuals is not as well …
-COVID-19 symptoms amongst individuals who experienced mild-to-moderate COVID-19 using …

… known COVID‐19 contact in the 2 wk before symptom onset. … and behaviors among
non‐hospitalized adults with COVID‐19 in … identify a close contact with a COVID‐19 case in the …

… some non-hospitalized patients showed a slight tendency towards a decrease of their
antibody titer, this study found that detection rates were similar in hospitalized or non-hospitalized …

… symptomatic nonhospitalized adults with COVID-19 [17]. The study population consists of
adults (… of COVID-19 at study entry, and ongoing symptoms within 48 hours prior to study entry. …

… options, the therapeutic armamentarium against COVID-19 must be strengthened [9]. … dose
SAB-185 in nonhospitalized adults with COVID-19 in the Accelerating COVID-19 Therapeutic …

… , adult PA dose. This might explain the lack of PA effect, on mild-to-moderate symptoms
post-COVID-19 … to reduce hospitalizations, and mortality rates as a result of COVID-19 infection. …

… more prevalent in hospitalized patients than in nonhospitalized patients (all P < 0.05; …
COVID-19 infection; there was no significant difference between hospitalized and nonhospitalized …

… in High-Risk Patients) compared NMV-r with placebo in unvaccinated, nonhospitalized
adults with mild–moderate COVID-19 at high risk of progression to severe disease [1]. This …